The BlackBerry Partners Fund is raising $100 million for affiliate fund focused on mobile investment opportunities in China. It is being launched as a joint venture with China Broadband Capital Partners.
3 min read · 27 May 2010
FTRANS, an Atlanta-based provider of accounts receivable and credit management solutions, has raised $4 million in new VC funding. Return backers include Greenhill SAVP, New Atlantic Ventures and Total Technology Ventures.
3 min read · 27 May 2010
Valeant Pharmaceuticals International (NYSE: VRX) has completed its $318 million acquisition of Aton Pharma Inc., a Lawrenceville, N.J.-based drug company focused on ophthalmology and certain orphan indications. Aton Pharma had raised over $37 million in VC funding from firms like Aisling Capital, HealthCare Ventures, Johnson & Johnson Development Corporation.
1 min read · 27 May 2010
Logical Therapeutics Inc., a Waltham, Mass.-based drug developer focused on inflammatory disease, has raised $16.9 million in Series C funding. SV Life Sciences led the round, and was joined by fellow return backers Burrill & Company, Novo A/S and Novitas Capital. The company previously raised over $30 million, and its lead compund is designed to reduce the gastrointestinal side effects of non-steroidal anti-inflammatory drugs.
2 min read · 27 May 2010
Heat Biologics, a Miami, Fla.-based off-the-shelf drug developer, has raised an undisclosed amount of first-round funding led by Brightline Ventures. The company's initial focus is on therapeutic vaccines to treat non small cell lung cancer.
3 min read · 27 May 2010
TRA Global, a New York-based provider of media planning, measurement and analytics software, has raised $18.2 million in Series C Funding. Intel Capital led the round with a $10 million investment, and was joined by return backers Arbitron and WPP.
3 min read · 27 May 2010
Energate, an Ontario-based provider of demand response and home energy management solutions, has raised C$7.2 million in Series B funding. Cycle Capital Fund led the round, and was joined by the Ontario Emerging Technology Fund.
3 min read · 27 May 2010
Noxxon Pharma AG, a German developer of biostable aptamers, has raised €33 million in Series D funding. NGN Capital led the round, and was joined by return backers TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH and the Dieckell Group. Noxxon raised a €37 million Series C round in May 2007.
5 min read · 27 May 2010
Vanedge Capital, a Canadian venture firm focused on interactive digital media, has closed its debut fund with C$100 million in capital commitments. Limited partners include Teralys Capital, BC Renaissance Capital Fund, BDC Venture Capital and Nicola Wealth Management Ltd.
5 min read · 27 May 2010
David Rosen has joined MPM Capital as an entrepreneur-in-residence. He previously was the head of corporate out-licensing at Pfizer.
1 min read · 27 May 2010
